Because activation of FXR increases apoptosis [10], [42] and decreases cell proliferation, and FXR is highly expressed in the intestines [8], targeted FXR overexpression and/or activation may provide an effective modality for treating CRC. This evidence concerns the gene NR1H4 and colorectal carcinoma.